 |
|
|
| Poster session 1: Chronic Myeloid Leukemia |
| Date: | Friday, June 11 2004 |
| Time: | 17:00-18:30 |
| Room: | |
| 17:00-18:30 |
108 |
|
|
CHARACTERIZATION OF GENOMIC DELETION OF 5' ABL AND 3' BCR IN DER (9) CHROMOSOME IN CHRONIC MYELOID LEUKEMIA AND RESPONSE TO IMATINIB MESYLATE
T.K. Saikia, C. Baisane, P.S. Amare-Kadam, K. Satam, N. Kabre, H. Jain, P.M. Parikh, C.D. Deshmukh (Mumbai (bombay), India)
| 17:00-18:30 |
109 |
|
|
IMATINIB RESTORES PLASMACYTOID DENDRITIC CELL FUNCTION IN CHRONIC MYELOID LEUKEMIA PATIENTS
M. Mohty, E. Jourdan, N. Ben Mami, D. Blaise, N. Vey, G. Damaj, D. Olive, B. Gaugler (Marseille, France)
| 17:00-18:30 |
110 |
|
|
DOSE-ADJUSTMENT OF IMATINIB BASED ON PLASMA LEVEL MEASUREMENT IN A PATIENT WITH CML
M. Heizmann, N. Widmer, L.A. Decosterd, A. Tobler, E. Oppliger Leibundgut (Basel, Switzerland)
| 17:00-18:30 |
111 |
|
|
ON THE EXPECTED SURVIVAL ADVANTAGE OF IMATINIB OVER IFN IN CHRONIC PHASE CML PATIENTS
M. Pfirrmann, J. Hasford (München, Germany)
| 17:00-18:30 |
112 |
|
|
TARGETING OF MCL-1 WITH ANTISENSE OLIGONUCLEOTIDES COUNTERACTS GROWTH AND VIABILITY OF CML CELLS: ROLE OF MCL-1 AS A NOVEL BCR/ABL-DEPENDENT TARGET IN CHRONIC MYELOID LEUKEMIA
K.J. Aichberger, M.M. Mayerhofer, S. Florian, H. Skvara, M.T. Krauth, C. Akgul, S. Derdak, W.F. Pickl, V. Wacheck, E. Selzer, B.P. Monia, P. Valent, C. Sillaber (Vienna, Austria)
| 17:00-18:30 |
113 |
|
|
ALPHA-1-ACID GLYCOPROTEIN SHOWS INCREASED BINDING TO IMATINIB AT NEW HIGHER DOSES RECENTLY PROPOSED
S.C. Paterson, K.D. Smith (Glasgow, United Kingdom)
| 17:00-18:30 |
114 |
|
|
CLINICAL SAFETY OF IMATINIB: A PROSPECTIVE STUDY OF POSSIBLE CLINICAL EFFECTS OF INHIBITION OF OTHER TYROSINE KINASES IN PATIENTS TREATED FOR CHRONIC-PHASE CML
J.F. Seymour, A.P. Grigg, M. Hertzberg, J. Matthews, K. Taylor, N. Guzzo-Pernell, A.K. Mills, M. Copeman, K. Lynch, T.P. Hughes (Melbourne, Australia)
| 17:00-18:30 |
115 |
|
|
SEMI-SYNTHETIC HOMOHARRINGTONINE FOR PATIENTS WITH CML IN ACCELERATED PHASE RESISTANT TO IMATINIB
J.M. Goldman, J. Kaeda, J.P. Robin, J.F. Apperley, D. Marin (London, United Kingdom)
| 17:00-18:30 |
116 |
|
|
AN INTERNATIONAL STUDY TO STANDARDIZE THE DETECTION OF BCR-ABL TRANSCRIPTS FROM STABILIZED PERIPHERAL BLOOD PREPARATIONS BY QUANTITATIVE RT-PCR
M.C. Mueller, G. Saglio, F. Lin, H. Pfeifer, R.D. Press, R.R. Tubbs, P. Paschka, E. Gottardi, S.G. O'Brien, O.G. Ottmann, H. Stockinger, M. Ben-Am, L. Wieczorek, K. Merx, U. Schwindel, R. Hehlmann, A. Hochhaus (Mannheim, Germany)
| 17:00-18:30 |
117 |
|
|
ANALYSIS OF IMATINIB THERAPY IN 300 PATIENTS WITH BCR-ABL POSITIVE LEUKEMIAS: EVALUATION OF RESPONSE AND RESISTANCE
T. Lahaye, U. Berger, B. Riehm, S. Kreil, M.C. Müller, K. Merx, P. Paschka, U. Schwindel, C. Schoch, H. Gschaidmeier, R. Hehlmann, A. Hochhaus (Mannheim, Germany)
| 17:00-18:30 |
118 |
|
|
THE INFLUENCE OF ARSENIC TRIOXIDE ON THE CLONOGENIC CAPACITY OF BONE MARROW IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CML.
W.K. Knopinska-Posluszny, W.P. Prejzner, I.T. Topolewska, A.H. Hellmann (Gdansk, Poland)
| 17:00-18:30 |
119 |
|
|
IMATINIB TREATMENT NORMALIZES ABERRANT NEUTROPHIL LEUKOTRIENE C4 SYNTHASE EXPRESSION IN PH CML PATIENTS – POTENTIAL INDICATOR OF P210 BCR-ABL SIGNALING
L. Ohm, C. Roos, L. Stenke, S. Widell, J. Lindgren, S. Tornhamre (Stockholm, Sweden)
| 17:00-18:30 |
120 |
|
|
CHRONIC MYELOID LEUKEMIA WITH AN UNCOMMON E8-INT-A2 BCR/ABL FUSION TRANSCRIPT (P200) AND ATYPICAL HEMATOLOGICAL FEATURES: A CASE REPORT.
D. Diverio, P. Niscola, L. Scaramucci, V. Gomes, N. Giuliani, F. Palombi, G. Luzi, M. Morucci, R. Foà, M. Montanaro (Rome, Italy)
| 17:00-18:30 |
121 |
|
|
CYTOGENETIC AND MOLECULAR MONITORING OF PH CHRONIC MYELOID LEUKEMIA (CML) CHILDREN AND YOUNG ADULTS TREATED WITH IMATINIB MESYLATE (STI571) THERAPY AT A SINGLE INSTITUTION
F. Giona, M.L. Moleti, M. Fava, C. Alfieri, G. Palumbo, A.M. Testi, E. Gottardi, M.R. De Cuia, D. Diverio, G. Saglio, R. Foà (Rome, Italy)
|